271 related articles for article (PubMed ID: 21062981)
1. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S
Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
Oneyama C; Ikeda J; Okuzaki D; Suzuki K; Kanou T; Shintani Y; Morii E; Okumura M; Aozasa K; Okada M
Oncogene; 2011 Aug; 30(32):3489-501. PubMed ID: 21383697
[TBL] [Abstract][Full Text] [Related]
3. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
[TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of the LGALS3 (galectin 3) gene in human non-small-cell lung cancer.
Yoshimura A; Gemma A; Hosoya Y; Komaki E; Hosomi Y; Okano T; Takenaka K; Matuda K; Seike M; Uematsu K; Hibino S; Shibuya M; Yamada T; Hirohashi S; Kudoh S
Genes Chromosomes Cancer; 2003 Jun; 37(2):159-64. PubMed ID: 12696064
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.
Kim YR; Oh JE; Kim MS; Kang MR; Park SW; Han JY; Eom HS; Yoo NJ; Lee SH
J Pathol; 2010 Mar; 220(4):446-51. PubMed ID: 19967722
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 activation involves an oxidative-stress independent pathway in tetrafluoroethylcysteine-induced cytotoxicity.
Ho HK; White CC; Fernandez C; Fausto N; Kavanagh TJ; Nelson SD; Bruschi SA
Toxicol Sci; 2005 Aug; 86(2):354-64. PubMed ID: 15901913
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals.
Surh YJ; Kundu JK; Na HK
Planta Med; 2008 Oct; 74(13):1526-39. PubMed ID: 18937164
[TBL] [Abstract][Full Text] [Related]
9. Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray.
Hu R; Xu C; Shen G; Jain MR; Khor TO; Gopalkrishnan A; Lin W; Reddy B; Chan JY; Kong AN
Life Sci; 2006 Oct; 79(20):1944-55. PubMed ID: 16828809
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway.
Shim GS; Manandhar S; Shin DH; Kim TH; Kwak MK
Free Radic Biol Med; 2009 Dec; 47(11):1619-31. PubMed ID: 19751820
[TBL] [Abstract][Full Text] [Related]
11. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis.
Satoh H; Moriguchi T; Takai J; Ebina M; Yamamoto M
Cancer Res; 2013 Jul; 73(13):4158-68. PubMed ID: 23610445
[TBL] [Abstract][Full Text] [Related]
12. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
[TBL] [Abstract][Full Text] [Related]
13. Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells.
Manandhar S; Lee S; Kwak MK
Arch Pharm Res; 2010 May; 33(5):717-26. PubMed ID: 20512470
[TBL] [Abstract][Full Text] [Related]
14. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
Hayes JD; McMahon M
Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
[TBL] [Abstract][Full Text] [Related]
15. HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells.
Malec V; Gottschald OR; Li S; Rose F; Seeger W; Hänze J
Free Radic Biol Med; 2010 Jun; 48(12):1626-35. PubMed ID: 20347035
[TBL] [Abstract][Full Text] [Related]
16. The transcriptome of Nrf2-/- mice provides evidence for impaired cell cycle progression in the development of cigarette smoke-induced emphysematous changes.
Gebel S; Diehl S; Pype J; Friedrichs B; Weiler H; Schüller J; Xu H; Taguchi K; Yamamoto M; Müller T
Toxicol Sci; 2010 May; 115(1):238-52. PubMed ID: 20133372
[TBL] [Abstract][Full Text] [Related]
17. Induction of Nrf2-regulated genes by 3H-1, 2-dithiole-3-thione through the ERK signaling pathway in murine keratinocytes.
Manandhar S; Cho JM; Kim JA; Kensler TW; Kwak MK
Eur J Pharmacol; 2007 Dec; 577(1-3):17-27. PubMed ID: 17854798
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
19. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
20. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
Sakakura C; Hasegawa K; Miyagawa K; Nakashima S; Yoshikawa T; Kin S; Nakase Y; Yazumi S; Yamagishi H; Okanoue T; Chiba T; Hagiwara A
Clin Cancer Res; 2005 Sep; 11(18):6479-88. PubMed ID: 16166423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
